Novochizol SA researches and develops applications of NOVOCHIZOL™ , a fist-in-class technology that transforms individual chitosan molecules into well-defined nanoparticles. Novochizol improves the characteristics of ordinary chitosans and yields materials with new properties for applications in pharma, medtech, biotech, agriculture, and other industries.
As a biocompatible biopolymer, NOVOCHIZOL™ improves the interfacing of different materials with living tissues. In in vitro diagnostics, Novochizol™ enables better nucleic acid purification and improves the specificity and sensitivity of PCR and immunological tests. As an excipient, Novochizol™ can be used to formulate small molecules, nucleic acids, peptides, proteins, viruses and cells. Novochizol™ formulations are strongly bioadherent, enabling sustained release of active ingredients, deep tissue penetration and intracellular targeting.
NOVOCHIZOL™ is the first chitosan-based nanoparticle compatible with pharma standards. Its starting material is a new type of biotech chitosan, manufactured by Alpha Chitin, a producer of precision chitosans with precise and reproducible physico-chemical characteristics, guaranteed traceability and batch-to-batch reproducibility. NOVOCHIZOL™ synthesis is also extremely well-defined: it is based on monomolecular, intramolecular cross-linking, in which a single linear molecule of chitosan is folded into a single nanoparticle. The outcome of the reactionis fully defined by the characteristics of the starting chitosan and the amount of the added cross-linking agent. In other words, the number of variables during synthesis is reduced to a strict minimum, yielding highly uniform particles that are easy to customize, to characterize, and to reproduce, in compliance with the regulatory requitements. NOVOCHIZOL™ meets all the criteria for Safe-by-Desing manufacturing.
As a drug delivery system, NOVOCHIZOL™ allows rapid formulation of all classes of active pharmaceutical ingredients: small molecules, peptides, nucleic acids, proteins, polysaccharides, viruses and mammalian cells. Different dosage forms are possible: injectables, topicals, aerosols, and implant coatings. The resulting formulations are strongly bioaadhesive and mucoadhesive, enabling localized delivery of APIs at the sire of administration, without systemic distribution. NOVOCHIZOL™ formulations ensure protection of fragile APIs against biological degradation and have customizable release properties. Importantly, they can be endocytosed at the site of administration in a receptor-independent manner, making it possible for APIs to reach new, intracelluar therapeutic targets. NOVOCHIZOL™ has an excellent safety profile as a polysaccharide that is fully biocompatible and biodegradable.
NOVOCHIZOL™ business model is based on two, convergent strategies: bona fide drug development and excipient registration and out-licensing of Novochizol™ as a drug delivery system. We are currently focusing on the development of new nanomedicines in immuno-concology (intra-tumoral delivery of therapetucally-effective doses of native and engineered cytokines), in respiratory diseases (inhalable drug delivery systems), and in cosmetic surgery and osteoarthritis (development of long-lasting formulations of hyaluronic acid as dermo fillers and for joint repair). We are leveraging on these early-stage drug development projects to reach regulatory qualification of Novochizol™ for pharmaceutical use in 2024) and to develop a rapid formulation testing platform for any API candidate that needs to be delivered to specific tissues or organs, avoiding systemic distribution.
NOVOCHIZOL™ aims to become the first chitosan nanoparticle approved for pharmaceutical use
As a biocompatible biopolymer, NOVOCHIZOL™ improves the interfacing of different materials with living tissues. In in vitro diagnostics, Novochizol™ enables better nucleic acid purification and improves the specificity and sensitivity of PCR and immunological tests. As an excipient, Novochizol™ can be used to formulate small molecules, nucleic acids, peptides, proteins, viruses and cells. Novochizol™ formulations are strongly bioadherent, enabling sustained release of active ingredients, deep tissue penetration and intracellular targeting.
NOVOCHIZOL™ is the first chitosan-based nanoparticle compatible with pharma standards. Its starting material is a new type of biotech chitosan, manufactured by Alpha Chitin, a producer of precision chitosans with precise and reproducible physico-chemical characteristics, guaranteed traceability and batch-to-batch reproducibility. NOVOCHIZOL™ synthesis is also extremely well-defined: it is based on monomolecular, intramolecular cross-linking, in which a single linear molecule of chitosan is folded into a single nanoparticle. The outcome of the reactionis fully defined by the characteristics of the starting chitosan and the amount of the added cross-linking agent. In other words, the number of variables during synthesis is reduced to a strict minimum, yielding highly uniform particles that are easy to customize, to characterize, and to reproduce, in compliance with the regulatory requitements. NOVOCHIZOL™ meets all the criteria for Safe-by-Desing manufacturing.
As a drug delivery system, NOVOCHIZOL™ allows rapid formulation of all classes of active pharmaceutical ingredients: small molecules, peptides, nucleic acids, proteins, polysaccharides, viruses and mammalian cells. Different dosage forms are possible: injectables, topicals, aerosols, and implant coatings. The resulting formulations are strongly bioaadhesive and mucoadhesive, enabling localized delivery of APIs at the sire of administration, without systemic distribution. NOVOCHIZOL™ formulations ensure protection of fragile APIs against biological degradation and have customizable release properties. Importantly, they can be endocytosed at the site of administration in a receptor-independent manner, making it possible for APIs to reach new, intracelluar therapeutic targets. NOVOCHIZOL™ has an excellent safety profile as a polysaccharide that is fully biocompatible and biodegradable.
NOVOCHIZOL™ business model is based on two, convergent strategies: bona fide drug development and excipient registration and out-licensing of Novochizol™ as a drug delivery system. We are currently focusing on the development of new nanomedicines in immuno-concology (intra-tumoral delivery of therapetucally-effective doses of native and engineered cytokines), in respiratory diseases (inhalable drug delivery systems), and in cosmetic surgery and osteoarthritis (development of long-lasting formulations of hyaluronic acid as dermo fillers and for joint repair). We are leveraging on these early-stage drug development projects to reach regulatory qualification of Novochizol™ for pharmaceutical use in 2024) and to develop a rapid formulation testing platform for any API candidate that needs to be delivered to specific tissues or organs, avoiding systemic distribution.
NOVOCHIZOL™ aims to become the first chitosan nanoparticle approved for pharmaceutical use
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
